Changeover at aap Implantate AG

Bruke Seyoum Alemu appointed as new CEO - Ongoing transformation to a leading trauma company keeping management continuity -

aap Implantate AG / Changeover at aap Implantate AG: Bruke Seyoum Alemu appointed as new CEO - Ongoing transformation to a leading trauma company keeping management continuity - . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG announced today that its Supervisory Board named Bruke Seyoum Alemu, 48, Chief Operating Officer of aap Implantate AG since 2008, as the company's new chairman of the Management Board and Chief Executive Officer, effective as of June 1, 2014.

With the receipt of the final purchase price instalment of EUR 6 million as well as with today's notarial acknowledgment, aap has successfully completed its previously announced sale of its Dutch subsidiary, EMCM B.V. Following the sale of EMCM, aap has accomplished a further milestone in its transformation to become a leading and focused trauma company. In view of the above, the Supervisory Board and the Management Board have agreed to reduce the size of aap's Management Board from three to two members. Current CEO Biense Visser and the Supervisory Board have agreed to terminate Mr. Visser's Management Board contract prematurely as of May 31^st, 2014.

Chairman of the Supervisory Board, Mr. Rubino di Girolamo, commented: "Under the leadership of Mr. Visser during the last 5 years, aap has been transformed into a focused trauma company with a solid financial position. The reduction of aap's management board reflects the reduced complexity and the increased transparency of aap's core activities and competencies: structure follows strategy. Further actions to reduce overheads have been identified and will be implemented this year. Based on his long standing experience with aap, Mr. Bruke Seyoum Alemu is well positioned to lead the company into its' next growth phase."

Mr. Visser commented: "Bruke has demonstrated focus in executing on the key initiatives since becoming Chief Operating Officer in December 2008. Our flagship in trauma activities, LOQTEQ®, has been developed and launched under his leadership. In addition, Bruke has been leading our profitable Center of Excellence for bone cements. That expertise, combined with his industry experience of more than 15 years, qualifies Bruke well to lead the company to an even greater success."